TipRanks
Takeda Pharmaceutical Company (TAK)
NYSE:TAK
US Market
TAK
Takeda Pharmaceutical Company
RESEARCH TOOLSreports
Want to see TAK full AI Analyst Report?

Takeda Pharmaceutical Company (TAK) Income Statement

1,366 Followers

Takeda Pharmaceutical Company Income Statement

Last quarter (Q1 2026), Takeda Pharmaceutical Company's total revenue was ¥1.22T, an increase of 10.23% from the same quarter last year. In Q1, Takeda Pharmaceutical Company's net income was ¥113.20B. See Takeda Pharmaceutical Company’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Mar 26Mar 25Mar 24Mar 23Mar 22
Total Revenue
¥ 4.78T¥ 4.58T¥ 4.26T¥ 4.03T¥ 3.57T
Gross Profit
¥ 2.44T¥ 3.00T¥ 2.83T¥ 2.78T¥ 2.46T
Operating Expenses
¥ 1.87T¥ 2.66T¥ 2.62T¥ 2.29T¥ 2.00T
Depreciation and Amortization
¥ 721.13B¥ 761.40B¥ 728.00B¥ 664.40B¥ 583.15B
EBITDA
¥ 1.38T¥ 1.21T¥ 1.23T¥ 1.28T¥ 1.18T
Operating Income
¥ 573.04B¥ 342.59B¥ 214.07B¥ 490.50B¥ 460.84B
Other Income/Expenses
¥ -297.16B¥ -167.50B¥ -161.28B¥ -115.42B¥ -158.27B
Pretax Income
¥ 275.88B¥ 175.08B¥ 52.79B¥ 375.09B¥ 302.57B
Net Income
¥ 203.33B¥ 107.93B¥ 144.07B¥ 317.02B¥ 230.06B
Per Share Metrics
Basic EPS
¥ 63.91¥ 34.17¥ 46.05¥ 102.15¥ 73.57
Diluted EPS
¥ 63.91¥ 33.62¥ 45.58¥ 100.97¥ 72.94
Weighted Average Shares Outstanding
 3.15B 3.21B 3.13B 3.10B 3.13B
Weighted Average Shares Outstanding (Diluted)
 3.21B 3.21B 3.16B 3.14B 3.15B
Currency in JPY

Takeda Pharmaceutical Company Earnings and Revenue History